Phase 1, open-label, dose-escalation study to assess the safety and pharmacokinetics of recombinant interleukin 21 (rIL-21) administered in combination with Rituxan (rituximab) in subjects with B-cell non-Hodgkin's lymphoma

Trial Profile

Phase 1, open-label, dose-escalation study to assess the safety and pharmacokinetics of recombinant interleukin 21 (rIL-21) administered in combination with Rituxan (rituximab) in subjects with B-cell non-Hodgkin's lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2008

At a glance

  • Drugs Denenicokin; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors ZymoGenetics
  • Most Recent Events

    • 31 Oct 2007 Status changed from recruiting to in progress.
    • 11 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top